0775.HK - CK Life Sciences Int'l., (Holdings) Inc.
HKSE - HKSE Delayed Price. Currency in HKD
At close: 04:08PM HKT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 0.780 |
| Open | 0.780 |
| Bid | 0.780 x 0 |
| Ask | 0.790 x 0 |
| Day's Range | 0.780 - 0.800 |
| 52 Week Range | 0.570 - 1.280 |
| Volume | |
| Avg. Volume | 2,859,405 |
| Market Cap | 7.593B |
| Beta (5Y Monthly) | 0.52 |
| PE Ratio (TTM) | 79.00 |
| EPS (TTM) | 0.010 |
| Earnings Date | Mar 14, 2023 |
| Forward Dividend & Yield | 0.01 (1.03%) |
| Ex-Dividend Date | May 23, 2023 |
| 1y Target Est | N/A |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- ACCESSWIRE
Wex Pharmaceuticals Inc. Enrolls the First Patient in The Phase 2b Clinical Trial Evaluating the Efficacy and Safety of Halneuron(R) In the Treatment of Chemotherapy-Induced Neuropathic Pain
WEX Pharmaceuticals Inc. ("WEX" or the "Company"), a biotechnology company developing Halneuron® (Tetrodotoxin or TTX) for pain, announced that the first patient has been dosed in its Phase 2B clinical trial evaluating the efficacy and safety of Tetrodotoxin in the treatment of Chemotherapy-Induced Neuropathic Pain (the "Clinical Trial").